


First-in-Class Small Molecule Approvals of 2022



Sunlenca

HIV-1 capsid inhibitor


(lenacapavir)

for multidrug resistant HIV-1 infection

INFECTIOUS DISEASES

927 mg SC Q6M after loading period

GILEAD



Sotyktu

TYK2 allosteric inhibitor


(deucravacitinib)

for moderate-to-severe plaque psoriasis

DERMATOLOGY

6 mg orally QD

BMS



Ztalmy

GABAA PAM


(ganaxolone)

for seizures in CDKL5 deficiency disorder

NEUROLOGY

6 mg/kg orally TID

MARINUS PHARMACEUTICALS



Pyrukynd

PK activator


(mitapivat)

for hemolytic anemia in PK deficiency

HEMATOLOGY

5 mg orally BID

AGIOS



Pluvicto

PSMA-targeted radiotherapy


(lutetium ¹⁷⁷Lu vipivotide tetraxetan)

for PSMA-positive prostate cancer

ONCOLOGY

7.4 GBq (200 mCi) IV Q6W up to 6 doses

NOVARTIS



Terlivaz

vasopressin receptor agonist


(terlipressin)

for hepatorenal syndrome in patients with reduced kidney function

HEPATOLOGY

starting dose: 0.85 mg IV Q6h on day 1-3

MALLINCKRODT



Voquezna

K⁺/H⁺-ATPase

potassium channel blocker


(vonoprazan*, amoxicillin, and clarithromycin)

for H. pylori infection

INFECTIOUS DISEASES

20 mg BID for 14 days in combo

TAKEDA



Camzyos

myosin inhibitor


(mavacamten)

for obstructive HCM

CARDIOLOGY

5 mg orally QD

BMS



Vtama

AhR agonist

(tapinarof)

for plaque psoriasis

DERMATOLOGY

1% cream topically QD

DERMAVANT SCIENCES



visit <https://drughunters.com/3Hgjlu6>

for more information on each drug including:

- how they were discovered
- how they work
- how they differentiate
- ...and more

drughunter.com

*novel component
CDER categorization of first-in-class based on mechanism of action
This poster is for informational purposes only and is not intended for medical use.

**drug
hunter**